Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colon Cancer Diagnosis With FAPI-PET Imaging
Sponsor: Turku University Hospital
Summary
Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool. The objective of this prospective study is to evaluate diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with colon cancer in primary staging and when suspected recurrence. 100 patients with colon cancer are enrolled and PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.
Official title: Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients With Colon Cancer
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-10-09
Completion Date
2026-10
Last Updated
2025-12-09
Healthy Volunteers
No
Conditions
Interventions
PET/CT ([F-18]FAPI-74)
PET/CT with FAPI-74 tracer is performed
Locations (1)
Turku PET Centre, Turku University Hospital
Turku, Finland